S&P 500   4,273.53 (-1.47%)
DOW   33,618.88 (-1.14%)
QQQ   354.21 (-1.50%)
AAPL   171.96 (-2.34%)
MSFT   312.14 (-1.70%)
META   298.96 (-0.62%)
GOOGL   128.57 (-1.94%)
AMZN   125.98 (-4.03%)
TSLA   244.12 (-1.16%)
NVDA   419.11 (-0.74%)
NIO   8.41 (+0.72%)
BABA   85.91 (-1.50%)
AMD   95.96 (-1.46%)
T   15.02 (-0.27%)
F   12.43 (-1.19%)
MU   67.94 (-0.93%)
CGC   0.92 (-2.20%)
GE   109.93 (-1.60%)
DIS   80.05 (-1.19%)
AMC   7.91 (-2.83%)
PFE   32.40 (-1.76%)
PYPL   58.93 (+0.12%)
NFLX   379.25 (-1.44%)
S&P 500   4,273.53 (-1.47%)
DOW   33,618.88 (-1.14%)
QQQ   354.21 (-1.50%)
AAPL   171.96 (-2.34%)
MSFT   312.14 (-1.70%)
META   298.96 (-0.62%)
GOOGL   128.57 (-1.94%)
AMZN   125.98 (-4.03%)
TSLA   244.12 (-1.16%)
NVDA   419.11 (-0.74%)
NIO   8.41 (+0.72%)
BABA   85.91 (-1.50%)
AMD   95.96 (-1.46%)
T   15.02 (-0.27%)
F   12.43 (-1.19%)
MU   67.94 (-0.93%)
CGC   0.92 (-2.20%)
GE   109.93 (-1.60%)
DIS   80.05 (-1.19%)
AMC   7.91 (-2.83%)
PFE   32.40 (-1.76%)
PYPL   58.93 (+0.12%)
NFLX   379.25 (-1.44%)
S&P 500   4,273.53 (-1.47%)
DOW   33,618.88 (-1.14%)
QQQ   354.21 (-1.50%)
AAPL   171.96 (-2.34%)
MSFT   312.14 (-1.70%)
META   298.96 (-0.62%)
GOOGL   128.57 (-1.94%)
AMZN   125.98 (-4.03%)
TSLA   244.12 (-1.16%)
NVDA   419.11 (-0.74%)
NIO   8.41 (+0.72%)
BABA   85.91 (-1.50%)
AMD   95.96 (-1.46%)
T   15.02 (-0.27%)
F   12.43 (-1.19%)
MU   67.94 (-0.93%)
CGC   0.92 (-2.20%)
GE   109.93 (-1.60%)
DIS   80.05 (-1.19%)
AMC   7.91 (-2.83%)
PFE   32.40 (-1.76%)
PYPL   58.93 (+0.12%)
NFLX   379.25 (-1.44%)
S&P 500   4,273.53 (-1.47%)
DOW   33,618.88 (-1.14%)
QQQ   354.21 (-1.50%)
AAPL   171.96 (-2.34%)
MSFT   312.14 (-1.70%)
META   298.96 (-0.62%)
GOOGL   128.57 (-1.94%)
AMZN   125.98 (-4.03%)
TSLA   244.12 (-1.16%)
NVDA   419.11 (-0.74%)
NIO   8.41 (+0.72%)
BABA   85.91 (-1.50%)
AMD   95.96 (-1.46%)
T   15.02 (-0.27%)
F   12.43 (-1.19%)
MU   67.94 (-0.93%)
CGC   0.92 (-2.20%)
GE   109.93 (-1.60%)
DIS   80.05 (-1.19%)
AMC   7.91 (-2.83%)
PFE   32.40 (-1.76%)
PYPL   58.93 (+0.12%)
NFLX   379.25 (-1.44%)
NASDAQ:ADMA

ADMA Biologics (ADMA) Stock Forecast, Price & News

$3.55
+0.06 (+1.72%)
(As of 05:18 PM ET)
Compare
Today's Range
$3.51
▼
$3.61
50-Day Range
$3.49
▼
$4.61
52-Week Range
$2.24
▼
$4.65
Volume
1.03 million shs
Average Volume
2.28 million shs
Market Capitalization
$798.43 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.00
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media

ADMA Biologics MarketRank™ Forecast

Analyst Rating
Buy
3.25 Rating Score
Upside/​Downside
69.0% Upside
$6.00 Price Target
Short Interest
Healthy
3.94% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Selling Shares
$9.88 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.06) to $0.12 Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.22 out of 5 stars

Medical Sector

331st out of 964 stocks

Biological Products, Except Diagnostic Industry

51st out of 159 stocks

See Top Rated MarketRank™ Stocks Here

ADMA stock logo

About ADMA Biologics (NASDAQ:ADMA) Stock

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. The company also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

ADMA Price History

ADMA Stock News Headlines

September 19, 2023 | americanbankingnews.com
ADMA Biologics (NASDAQ:ADMA) Cut to "Sell" at StockNews.com
September 14, 2023 | msn.com
Adma Biologics (ADMA) Stock Sinks As Market Gains: What You Should Know
September 26, 2023 | Micro-Cap Stock Trader (Ad)
Unlock the treasure on Mount Olympus with this little-known mining stock.
Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons
September 13, 2023 | finance.yahoo.com
Is It Worth Investing in Adma Biologics (ADMA) Based on Wall Street's Bullish Views?
September 6, 2023 | finance.yahoo.com
Institutional investors are ADMA Biologics, Inc.'s (NASDAQ:ADMA) biggest bettors and were rewarded after last week's US$56m market cap gain
August 31, 2023 | msn.com
Adma Biologics (ADMA) Price Target Increased by 17.07% to 6.12
August 26, 2023 | seekingalpha.com
ADMA Biologics: From Plasma To Profits With A Pinch Of Prudence
August 11, 2023 | msn.com
Cantor Fitzgerald Maintains Adma Biologics (ADMA) Overweight Recommendation
September 26, 2023 | Micro-Cap Stock Trader (Ad)
Unlock the treasure on Mount Olympus with this little-known mining stock.
Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons
August 10, 2023 | finanznachrichten.de
ADMA Biologics, Inc.: ADMA Biologics Announces Second Quarter 2023 Financial Results and Provides Business Update
August 10, 2023 | msn.com
HC Wainwright & Co. Maintains Adma Biologics (ADMA) Buy Recommendation
August 10, 2023 | finance.yahoo.com
Why Shares of ADMA Biologics Are Climbing Thursday
August 10, 2023 | finance.yahoo.com
Is ADMA Biologics (ADMA) Outperforming Other Medical Stocks This Year?
August 10, 2023 | msn.com
Raymond James Maintains Adma Biologics (ADMA) Strong Buy Recommendation
August 10, 2023 | markets.businessinsider.com
ADMA Biologics (ADMA) Gets a Buy from H.C. Wainwright
August 10, 2023 | finance.yahoo.com
Q2 2023 ADMA Biologics Inc Earnings Call
August 9, 2023 | msn.com
ADMA Biologics GAAP EPS of -$0.03 in-line, revenue of $60.13M beats by $4.63M
August 9, 2023 | finance.yahoo.com
ADMA Biologics Announces Second Quarter 2023 Financial Results and Provides Business Update
August 2, 2023 | finance.yahoo.com
ADMA Biologics to Report Second Quarter 2023 Financial Results on August 9, 2023
July 28, 2023 | finance.yahoo.com
ADMA Biologics (ADMA) to Report Q2 Earnings: What's in Store?
July 20, 2023 | finance.yahoo.com
Adma Biologics (ADMA) Gains As Market Dips: What You Should Know
July 19, 2023 | finance.yahoo.com
ADMA BioCenters Receives FDA Approval for its Ninth Plasma Collection Center, Located in Dallas, GA
July 13, 2023 | msn.com
Adma Biologics (ADMA) Gains But Lags Market: What You Should Know
June 23, 2023 | finance.yahoo.com
Aeglea (AGLE) Soars 329% on Acquiring Spyre Therapeutics
June 21, 2023 | msn.com
Aridis (ARDS) Up on Regulatory Update for Pneumonia Drug
June 21, 2023 | finance.yahoo.com
Merck's (MRK) Gastric Cancer Study Fails to Meet a Primary Goal
June 16, 2023 | finance.yahoo.com
Mersana (MRSN) Down on Partial Ovarian Cancer Study Hold
See More Headlines
Receive ADMA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ADMA Biologics and its competitors with MarketBeat's FREE daily newsletter.

ADMA Company Calendar

Last Earnings
8/09/2023
Today
9/26/2023
Next Earnings (Estimated)
11/08/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ADMA
CUSIP
N/A
CIK
1368514
Web
www.admabiologics.com
Phone
(201) 478-5552
Fax
201-478-5553
Employees
617
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$6.00
High Stock Price Forecast
$7.00
Low Stock Price Forecast
$5.00
Forecasted Upside/Downside
+68.5%
Consensus Rating
Buy
Rating Score (0-4)
3.25
Research Coverage
4 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($0.20)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-65,900,000.00
Net Margins
-19.36%
Pretax Margin
-19.36%
Return on Equity
-27.55%
Return on Assets
-11.26%

Debt

Debt-to-Equity Ratio
1.03
Current Ratio
6.35
Quick Ratio
2.49

Sales & Book Value

Annual Sales
$154.08 million
Price / Sales
5.20
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.69 per share
Price / Book
5.16

Miscellaneous

Outstanding Shares
224,910,000
Free Float
211,637,000
Market Cap
$800.68 million
Optionable
Optionable
Beta
0.81
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

  • Mr. Adam S. GrossmanMr. Adam S. Grossman (Age 46)
    Co-Founder, Pres, CEO & Director
    Comp: $1.52M
  • Dr. Jerrold B. Grossman D.P.S. (Age 75)
    Ph.D., Co-Founder & Vice Chairman
    Comp: $80k
  • Mr. Brian Lenz CPAMr. Brian Lenz CPA (Age 51)
    CPA, Exec. VP, CFO & GM of ADMA BioCenters
    Comp: $1.08M
  • Ms. Kaitlin Kestenberg
    Sr. VP of Compliance & Project Operations
  • Mr. Drew Pantello
    VP of Marketing & Corp. Devel.
  • Mr. Neal C. Fitzpatrick
    VP of Sales
  • Ms. Cindy Petersen
    Exec. Director of HR
  • Mr. Skyler Bloom
    Sr. Director of Bus. Devel. & Corp. Strategy

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













ADMA Stock - Frequently Asked Questions

Should I buy or sell ADMA Biologics stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for ADMA Biologics in the last twelve months. There are currently 3 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" ADMA shares.
View ADMA analyst ratings or view top-rated stocks.

What is ADMA Biologics' stock price forecast for 2023?

4 Wall Street analysts have issued 1 year price objectives for ADMA Biologics' shares. Their ADMA share price forecasts range from $5.00 to $7.00. On average, they expect the company's share price to reach $6.00 in the next twelve months. This suggests a possible upside of 68.5% from the stock's current price.
View analysts price targets for ADMA or view top-rated stocks among Wall Street analysts.

How have ADMA shares performed in 2023?

ADMA Biologics' stock was trading at $3.88 at the start of the year. Since then, ADMA stock has decreased by 8.2% and is now trading at $3.56.
View the best growth stocks for 2023 here.

When is ADMA Biologics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 8th 2023.
View our ADMA earnings forecast.

How were ADMA Biologics' earnings last quarter?

ADMA Biologics, Inc. (NASDAQ:ADMA) announced its quarterly earnings results on Wednesday, August, 9th. The biotechnology company reported ($0.02) EPS for the quarter, meeting the consensus estimate of ($0.02). The biotechnology company had revenue of $60.12 million for the quarter, compared to analysts' expectations of $55.45 million. ADMA Biologics had a negative net margin of 19.36% and a negative trailing twelve-month return on equity of 27.55%. During the same period in the prior year, the firm posted ($0.07) earnings per share.

What ETF holds ADMA Biologics' stock ?

Virtus LifeSci Biotech Products ETF holds 88,335 shares of ADMA stock, representing 1.90% of its portfolio.

What guidance has ADMA Biologics issued on next quarter's earnings?

ADMA Biologics updated its FY 2025 earnings guidance on Thursday, August, 10th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $325.00M-.

What is Adam S. Grossman's approval rating as ADMA Biologics' CEO?

9 employees have rated ADMA Biologics Chief Executive Officer Adam S. Grossman on Glassdoor.com. Adam S. Grossman has an approval rating of 29% among the company's employees. This puts Adam S. Grossman in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of ADMA Biologics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ADMA Biologics investors own include Matinas BioPharma (MTNB), Pennsylvania Real Estate Investment Trust (PEI), Organigram (OGI), Gran Tierra Energy (GTE), Tilly's (TLYS), Bionano Genomics (BNGO), Novan (NOVN), CNBX Pharmaceuticals (CNBX), Zosano Pharma (ZSAN) and DHT (DHT).

What is ADMA Biologics' stock symbol?

ADMA Biologics trades on the NASDAQ under the ticker symbol "ADMA."

Who are ADMA Biologics' major shareholders?

ADMA Biologics' stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.36%), State Street Corp (4.73%), Stonepine Capital Management LLC (3.96%), Nuveen Asset Management LLC (3.85%), Nuveen Asset Management LLC (3.85%) and AWM Investment Company Inc. (2.71%). Insiders that own company stock include Adam S Grossman, Brian Lenz, Bryant Fong, Jerrold B Grossman, Perceptive Advisors Llc and Young Kwon.
View institutional ownership trends.

How do I buy shares of ADMA Biologics?

Shares of ADMA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ADMA Biologics' stock price today?

One share of ADMA stock can currently be purchased for approximately $3.56.

How much money does ADMA Biologics make?

ADMA Biologics (NASDAQ:ADMA) has a market capitalization of $800.68 million and generates $154.08 million in revenue each year. The biotechnology company earns $-65,900,000.00 in net income (profit) each year or ($0.20) on an earnings per share basis.

How many employees does ADMA Biologics have?

The company employs 617 workers across the globe.

How can I contact ADMA Biologics?

ADMA Biologics' mailing address is 465 STATE ROUTE 17, RAMSEY NJ, 07446. The official website for the company is www.admabiologics.com. The biotechnology company can be reached via phone at (201) 478-5552, via email at info@admabio.com, or via fax at 201-478-5553.

This page (NASDAQ:ADMA) was last updated on 9/26/2023 by MarketBeat.com Staff

My Account -